ARTICLE | Clinical News

Lirilumab combo shows early promise in SCCHN

November 9, 2016 12:16 AM UTC

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from a Phase I/II trial of lirilumab (IPH2102) plus PD-1 inhibitor Opdivo nivolumab that suggest the combination may offer a clinical benefit in patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).

The efficacy data are the first for Innate’s lead program, a human mAb against killer cell immunoglobulin-like receptors (KIRs). In 2011, the French biotech granted Bristol-Myers Squibb Co. (NYSE:BMY) exclusive, worldwide rights to lirilumab. BMS markets Opdivo to treat several cancers (see BioCentury, Nov. 7)...